

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO Box 1450 Alexandra, Virginia 22313-1450 www.repto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/574,337	05/09/2006	Seong Hwan Cho	1751-0400	8934	
6449 7550 ROTHWELL, FIGG, ERNST & MANBECK, P.C. 1425 K STREET, N.W. SUITE 800 WASHINGTON, DC 20005			EXAM	EXAMINER	
			LEWIS, AMY A		
			ART UNIT	PAPER NUMBER	
			1614		
			NOTIFICATION DATE	DELIVERY MODE	
			12/31/2008	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PTO-PAT-Email@rfem.com

Application No. Applicant(s) 10/574,337 CHO ET AL. Office Action Summary Examiner Art Unit Amy A. Lewis 1614 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 08 August 2008. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-16 is/are pending in the application. 4a) Of the above claim(s) _____ is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 1-16 is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s)

1) Notice of References Cited (PTO-892)

Paper No(s)/Mail Date 3/13/07

Notice of Draftsperson's Patent Drawing Review (PTO-948)
 Notice of Draftsperson's Patent Drawing Review (PTO-948)
 Notice of Draftsperson's Patent Drawing Review (PTO-948)

Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.

6) Other:

5) Notice of Informal Patent Application

Application/Control Number: 10/574,337 Page 2

Art Unit: 1614

DETAILED ACTION

Election/Restrictions

Applicant's election without traverse of the species tamsulosin in the reply filed on 8/8/08 is acknowledged.

Applicant's election with traverse of the species of the following polymers is also acknowledged:

- (i) hydroxypropylmethyleelhulose as the polymer for the sustained-release core which reads on claims 5 and 6 and the generic claims 1-3 and 7-16;
- (ii) a copolymer of methacrylic acid and ethylacrylate as the polymer for the enteric film coating layer which reads on claim 11 and generic claims 1-10 and 12-16;
- (iii) polyvinyl alcohol as the polymer for the active ingredient-containing film coating layer which reads on claim 12 and generic claims 1-11 and 13-16; and
- (iv) a copolymer of methacrylic acid and ethylacrylate as the polymer for the outer coating layer which reads on claim 11 and generic claims 1-10 and 12-16

Applicant's election of polymer species as outlined above (see the reply at page 3) is acknowledged. The traversal is on the ground(s) that the election should be made regarding each component part of the formulation.

Accordingly, the application will be examined as far as it reads upon the elected species acknowledged above. The species election requirement is still deemed proper and is therefore made FINAL.

Priority

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Art Unit: 1614

However, certified English translations have not been provided. Thus, priority is currently given as far as PCT/KR04/02496 filed 9/25/2004.

Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)(d) prior to declaration of an interference, a certified English translation of the foreign
application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure
to provide a certified translation may result in no benefit being accorded for the non-English
application.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Shinoda et al. (U.S. Patent Appl. Pub. No. 20030147948).

The reference teaches a enteric tamsulosin hydrochloride composition comprising

sustained-release fine particles, containing sustained-release fine particles that can be used in quick-disintegrating tablets in the buccal cavity (see: abstract and claims 1-4, and 7-9; Example 1). The polymer substance of the formulation is hydroxypropylmethylcellulose and ethylacrylate (see: claim 9; [0019], [0031] and [0055]). The reference teaches that the water soluble polymer used in the formulation include polyvinyl alcohol (see [0055-0057]). The reference teaches weight ratios which overlap with that of the instant invention (see claims 1-5; Example 1; [0052]).

Application/Control Number: 10/574,337

Art Unit: 1614

Functional limitations are recited in instant claims 3, 4, 8, and 9. The claims are drawn to viscosity and pH-dependency. In the absence of a showing that these mechanisms of action are not present in the claimed sustained release polymer, one skilled in the art would have considered such properties to be inherent in the claimed tamsulosin formulation.

It is noted that *In re Best* (195 USPQ 430) and *In re Fitzgerald* (205 USPQ 594) discuss the support of rejections wherein the prior art discloses subject matter, which there is reason to believe inherently includes functions that are newly cited, or is identical to a product instantly claimed. In such a situation the burden is shifted to the applicants to "prove that subject matter to be shown in the prior art does not possess the characteristic relied on" (205 USPQ 594, second column, first full paragraph). There is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the time of invention, but only that the subject matter is in fact inherent in the prior art reference. *Schering Corp. v. Geneva Pharm. Inc.*, 339 F.3d 1373, 1377, 67 USPQ2d 1664, 1668 (Fed. Cir. 2003); see also *Toro Co. v. Deere & Co.*, 355 F.3d 1313, 1320, 69 USPQ2d 1584, 1590 (Fed. Cir. 2004) ("IT]he fact that a characteristic is a necessary feature or result of a prior-art embodiment (that is itself sufficiently described and enabled) is enough for inherent anticipation, even if that fact was unknown at the time of the prior invention").

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy A. Lewis whose telephone number is 571-272-9032. The examiner can normally be reached on Monday-Friday 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Amy A Lewis/ Examiner, Art Unit 1614

/Ardin Marschel/ Supervisory Patent Examiner, Art Unit 1614